ResMed, Inc. (NYSE:RMD)
| CAPS Rating |
|
|---|---|
| Open | $29.62 |
| Previous Close | $29.92 |
| Daily Range | $29.48 - $29.81 |
| 52-Week Range | $23.37 - $35.32 |
| Market Cap | $4.50B |
| P/E Ratio | 21.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 690,217 |
| Average Daily Volume | 0 |
RMD
VS S&P 500 (SPY)
How do you think RMD will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
RMD Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
RMD News and Commentary
- Are These Medical Companies Cash Kings? – The Motley Fool
- ResMed Passes This Key Test – The Motley Fool
- Mixed 2Q for ResMed - Analyst Blog – NASDAQ
- ResMed Beats Analyst Estimates on EPS – The Motley Fool
- ResMed Shares Popped: What You Need to Know – The Motley Fool
- Australian Stock Market Report – Midday 1/27/2012 – NASDAQ
- ResMed Passes This Key Test – The Motley Fool
- 1 Reason ResMed May Be Headed for a Slowdown – The Motley Fool
- Does ResMed Pass Buffett's Test? – The Motley Fool
- ResMed Shares Plunged: What You Need to Know – The Motley Fool
- Australian Stock Market Report - Afternoon 10/25/2011 – NASDAQ
- Australian Stock Market Report - Midday 10/25/2011 – NASDAQ
- ResMed's Management Is Creating Value – The Motley Fool
- 3 Stocks to Beat a Recession – The Motley Fool
- RMD – Blog at The Motley Fool
- 4-Star Stocks Poised to Pop: ResMed – The Motley Fool
- ResMed's CEO Discusses Q4 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- UPDATE 1-ResMed quarterly profit rises 10 pct – Reuters
- ResMed Earnings Preview – The Motley Fool
- Does ResMed Pass Buffett's Test? – The Motley Fool
RSS Headlines
Fool UK
